AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Corticosteroid
Description: Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotrovimab
Description: UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Molnupiravir
Description: Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid
Description: UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil
Description: Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose corticosteroids: Dexamethasone
Description: Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose corticosteroids: Dexamethasone
Description: ≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Study NCT01338012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal F
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal F
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is > 13 mm in diameter~ * if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~* Dosing to continue until administration of hCG (see below).
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is > 13 mm in diameter~ * if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~* Dosing to continue until administration of hCG (see below).
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is > 13 mm in diameter~ * if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~* Dosing to continue until administration of hCG (see below).
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is > 13 mm in diameter~ * if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~* Dosing to continue until administration of hCG (see below).
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: - 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter
Study NCT00439829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: - 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter
Study NCT02091739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (100 Units)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT02091739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (75 Units)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT02091739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT01705808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Protein C concentrate
Study NCT01705808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protein C concentrate
Study NCT01250964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens insertion during cataract surgery
Description: After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
Study NCT00405353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel 10 grams of gel containing 100 mg of testosterone
Description: testosterone gel
Study NCT00823004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: letrozole 5mg/day from day 3 to day 7 of menstrual cycle
Study NCT00823004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive (Marvelone)
Description: oral contraceptive, first 21 days
Study NCT02228239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
Study NCT01760486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island
Study NCT00823004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist (buserelin)
Description: 50 µg SC twice daily
Study NCT00823004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH or hMG
Description: recombinant FSH or hMG 300-450 IU/day
Study NCT01760486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape Up Rhode Island + Professional Coach + Incentives
Study NCT01760486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape Up Rhode Island + Peer Coach + Incentives
Study NCT03229447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLearning Modules
Description: All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
Study NCT03229447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eLearning Modules
Description: All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
Study NCT03229447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change Team Intervention
Description: Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
Study NCT01075230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
Study NCT01760967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intervention to administer dexmedetomidine or not
Study NCT00823004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganirelix acetate
Description: GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
Study NCT00211978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium acetate
Description: 667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
Study NCT00211978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
Study NCT01903928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: injection
Study NCT01189617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PD-F-7619
Description: Off-White to Beige Lotion
Study NCT03380221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon
Description: Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
Study NCT03380221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat cookies
Description: Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
Study NCT00545246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (AVE0005)
Description: intravenous infusion
Study NCT00545246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: intravenous infusion
Study NCT01729338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \[10,12,14, etc.\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
Study NCT01729338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
Study NCT01729338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide (odd cycles \[9,11,13, etc.\]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately.
Study NCT00395941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT00395941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Acitretin
Study NCT02205008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: Total or subtotal gastrectomy with D2
Study NCT02205008 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgery
Description: Total or subtotal gastrectomy with D2
Study NCT02205008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant systemic chemotherapy
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
Study NCT02205008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: adjuvant systemic chemotherapy
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
Study NCT02205008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early postoperative intraperitoneal chemothgerapy
Description: operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
Study NCT04014166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
Study NCT05028127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be receiving bimekizumab at pre-specified time-points.
Study NCT02716831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling & Acceptance-based Therapy
Study NCT02716831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Eating Disorders
Study NCT00532194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cediranib
Description: Once-daily oral tablet starting dose 20mg
Study NCT04053140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
Study NCT04053140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array and closed-loop control of penicillin delivery
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
Study NCT02569359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: shea nut oil extract
Study NCT02569359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00345163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00345163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intravenous repeating dose
Study NCT02527070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPeRATE (Paced Breathing)
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
Study NCT02527070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE (Paced Breathing)
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
Study NCT02527070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Warp10 (Red LED)
Study NCT02527070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnilux new-U (Near Infrared LED)
Study NCT02527070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat/cold provocation
Description: Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
Study NCT02527070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat/cold provocation
Description: Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
Study NCT01810627 — intervention group
Intervention type: RADIATION
Intervention: MVCT
Description: Patients will receive an additional MVCT scan at their one month follow up visit.
Study NCT01998594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
Study NCT01998594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty
Description: A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
Study NCT01639105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: 10 600 NM ABLATIEVE FRACTIONATED LASER
Study NCT03735160 — intervention group
Intervention type: DEVICE
Intervention: pressure sensor
Description: Pressure sensor at the angle of intratracheal tube and nasal alar